Skip to main content
Skip to content
Case File
kaggle-ho-024681House Oversight

Cannabis Industry Segmentation Overview – Product Sales by Category (Q3 2017)

Cannabis Industry Segmentation Overview – Product Sales by Category (Q3 2017) The passage provides generic market data on cannabis product categories with no mention of influential individuals, agencies, financial flows, or misconduct. It lacks actionable leads or controversial content. Key insights: Three main cannabis consumption categories: flower, concentrates, infused products.; Q3 2017 sales distribution for CO, OR, WA: 51% flower, 23% concentrates, 14% edibles, 12% other.; Infused products have slower onset but longer duration compared to inhaled forms.

Date
Unknown
Source
House Oversight
Reference
kaggle-ho-024681
Pages
1
Persons
2
Integrity
No Hash Available

Summary

Cannabis Industry Segmentation Overview – Product Sales by Category (Q3 2017) The passage provides generic market data on cannabis product categories with no mention of influential individuals, agencies, financial flows, or misconduct. It lacks actionable leads or controversial content. Key insights: Three main cannabis consumption categories: flower, concentrates, infused products.; Q3 2017 sales distribution for CO, OR, WA: 51% flower, 23% concentrates, 14% edibles, 12% other.; Infused products have slower onset but longer duration compared to inhaled forms.

Tags

kagglehouse-oversightcannabis-marketproduct-segmentationindustry-analysissales-data

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
KR L PI L AC BL CA TA CHAPTER IIl_ Cannabis Industry Segmentation = Consumer Products Cannabis may be consumed in many different forms, which fall into three broad categories: flower, concentrates and infused products. The most popular way to consume cannabis historically has been to smoke the flower or “bud” from the cannabis plant, which can be done using a pipe, a hand-rolled cigarette (often referred to as a “joint”) or a water pipe (often referred to as a “bong”). Cannabis flower can also be vaporized and inhaled (using a product known as a “vaporizer”). The active compounds in cannabis can be extracted and concentrated into oil or waxlike substances known as concentrates. Concentrates, in turn, can either be vaporized and inhaled or infused into products known as “infused products.” Infused products may be applied topically, such as lotions and creams, or consumed orally, such as food and drinks (known as “edibles”), capsules, pills and tinctures. When smoke or vapor from heated flower or a concentrate is inhaled, the active compounds travel directly to the central nervous system and the physiological effects typically begin within one to five minutes. When infused products are consumed orally, the active compounds are digested in the stom- ach and metabolized by the liver before taking effect, typically in one to two hours. Compared. to inhaled products, infused products deliver a smaller relative amount of cannabinoids to the blood- stream, but they produce longer-lasting effects. Innovative companies continue to expand the universe of cannabis products, developing brands with packaging that increasingly emphasizes education about the product’s effects and appeals to main- stream consumers. Cannabis flower is currently the most widely sold form of cannabis, but concen- trates and infused products are gaining in popularity. The following chart shows the combined relative sales by product category for Colorado, Oregon and Washington (three states with relatively mature recreational and medical cannabis markets) for the three months ended September 30, 2017. Product Sales by Category: Q3 2017 14% 12% 51% 23% @ Flower @ Concentrates @ Edibles § Other Source: BDS Analytics © 2017 Ackrell Capital, LLC | Member FINRA/SIPC 45

Related Documents (6)

House OversightFeb 26, 2019

Cowen CBD Market Outlook Report – No Evident Investigative Leads

Cowen CBD Market Outlook Report – No Evident Investigative Leads The document is a commercial research note on CBD market size and analyst ratings, containing no references to political figures, financial misconduct, or intelligence activities. It offers no actionable investigative leads. Key insights: Provides market size estimate for U.S. CBD ($16 bn by 2025).; Cites a proprietary survey showing 7% adult usage.; Mentions analyst ratings for WEED, TLRY, TPB.

1p
House OversightUnknown

Deep Thinking – collection of essays by AI thought leaders

Deep Thinking – collection of essays by AI thought leaders The document is a largely philosophical and historical overview of AI research, its thinkers, and societal implications. It contains no concrete allegations, financial transactions, or novel claims that point to actionable investigative leads involving influential actors. The content is primarily a synthesis of known public positions and historical anecdotes, offering limited new information for investigative follow‑up. Key insights: Highlights concerns about AI risk and alignment voiced by prominent researchers (e.g., Stuart Russell, Max Tegmark, Jaan Tallinn).; Notes the growing corporate influence on AI development (e.g., references to Google, Microsoft, Amazon, DeepMind).; Mentions historical episodes where AI research intersected with military funding and government secrecy.

1p
House OversightUnknown

Synthetic Cannabis Overview Lacks Investigative Leads

Synthetic Cannabis Overview Lacks Investigative Leads The document is a generic informational summary about cannabinoids with no mention of individuals, transactions, or wrongdoing. It provides no actionable leads, novel allegations, or connections to powerful actors. Key insights: Describes types of cannabinoids and FDA approvals.; Lists potential therapeutic uses of various phytocannabinoids.; Cites Cowen and Company as source.

1p
House OversightUnknown

NLRB Notice Draft Comments on Union Insignia, Spying, and Employer Conduct

NLRB Notice Draft Comments on Union Insignia, Spying, and Employer Conduct The passage is a regulatory notice from the National Labor Relations Board discussing draft language on union rights and employer conduct. It contains no specific allegations, financial flows, or links to high‑profile officials or entities. The only potential leads are generic references to comments from interest groups (Heritage Foundation, National Immigration Law Center) but they do not provide actionable evidence of misconduct. Key insights: Comments from the Heritage Foundation and National Immigration Law Center propose additions to the NLRB notice.; The Board rejects suggestions to expand the notice with specific employer retaliation examples.; Discussion of “special circumstances” for prohibiting union insignia and clarification on spying/videotaping rules.

1p
House OversightUnknown

Supreme Court Slip Opinion on International Finance Corp. Immunity

Supreme Court Slip Opinion on International Finance Corp. Immunity The passage discusses legal doctrine on international organization immunity without mentioning any wrongdoing, financial misconduct, or high‑profile individuals. It offers no actionable leads, novel allegations, or controversial connections to powerful actors. Key insights: Clarifies that the International Organizations Immunities Act grants IOs the same immunity as foreign governments under FSIA.; Notes the case involves IFC's loan to an Indian coal plant and plaintiffs' environmental claims.; Affirms lower court's dismissal based on immunity doctrine.

1p
House OversightOtherNov 11, 2025

NLRB Notice Draft Comments on Union Insignia, Spying, and Employer Conduct

The passage is a regulatory notice from the National Labor Relations Board discussing draft language on union rights and employer conduct. It contains no specific allegations, financial flows, or link Comments from the Heritage Foundation and National Immigration Law Center propose additions to the N The Board rejects suggestions to expand the notice with specific employer retaliation examples. Di

3p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.